2024-02-13T00:00:00.000+11:00
Ongoing

FURMO-002

FURMO-002
Lung cancer

A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumor activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.

A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumor activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Lung cancer

Study Phase

1b

Trial registration
GenesisCare Location(s)

GenesisCare North Shore 

GenesisCare North Shore  :::
Principal Investigator(s)

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.